Document is current
Any future updates will be listed below
-
Authors
Wakayama, Shonosuke
Takahashi, Shin
Ouchi, Kota
Sakamoto, Yasuhiro
Denda, Tadamichi
Takashima, Atsuo
Komatsu, Yoshito
Nakamura, Masato
Ohori, Hisatsugu
Yamaguchi, Tatsuro
Kobayashi, Yoshimitsu
Baba, Hideo
Kotake, Masanori
Amagai, Kenji
Kondo, Hitoshi
Shimada, Ken
Yamada, Yasuhide
Sato, Atsushi
Yuki, Satoshi
Okita, Akira
Komine, Keigo
Watanabe, Mika
Morita, Satoshi
Ishioka, Chikashi
-
Funding
Funding for this research was provided by:
the Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research (JP25K10554)
the Tokyo Cooperative Oncology Group with funding from Taiho Pharmaceutical Co. Ltd., Japan (no number)
the Project for Development of Innovative Research on Cancer Therapeutics (11110018)
the Project for Cancer Research and Therapeutic Evolution (16770660)
the Japan Agency for Medical Research and Development Agency (the Japan Agency for Medical Research and Development Agency (AMED))
- License Information
-
More Information
Article History
Received: 31 July 2025
Accepted: 24 February 2026
First Online: 8 March 2026
Declarations
:
: Dr. Shin Takahashi reports honoraria from Taiho, Chugai, Asahi Kasei, Bristol-Myers Squibb, Bayer, Japan blood products organization, Medicon, Takeda, Yakult, and Daiichi Sankyo, Eli Lilly, Eisai, and grants and personal fees from Merck Biopharma and Ono, outside the submitted work; Prof. Yoshito Komatsu reports grants and personal fees from Taiho, grants and personal fees from Chugai, personal fees from Takeda, grants and personal fees from Bayer, grants and personal fees from Sanofi, grants and personal fees from Ono, grants from MSD, grants and personal fees from Yakult, grants from NanoCarrier, grants from QuintilesIMS, grants from Sysmex, grants and personal fees from Mediscience planning, grants from Dainippon Sumitomo Pharma, personal fees from Kyowa Kirin, personal fees from Asahi Kasei, grants from Nippon Zoki Pharmaceutical, grants from A2 Healthcare, grants and personal fees from Daiichi Sankyo, grants from Eisai, grants from Parexel International, grants from Astellas, grants from Incyte, grants from Syneos health clinical, personal fees from Eli Lilly, personal fees from Nipro, personal fees from Bristol-Myers Squibb, personal fees from Moroo, personal fees from Pfizer, personal fees from Merck Biopharma, personal fees from Medical Review, personal fees from Mitsubishi Tanabe Pharma, personal fees from Nippon Kayaku, personal fees from Shire Japan, personal fees from Novartis, personal fees from Otsuka Pharmaceutical Factory, personal fees from 3H Medi Solution, grants from Shionogi, grants from ShiftZero, outside the submitted work; Dr. Atsushi Sato reports research grants from Chugai, Taiho, and Daiichi-Sankyo, and honoraria from Chugai and Taiho, outside the submitted work; Dr. Satoshi Yuki reports honoraria from Chugai Pharmaceutical, Eli Lilly, Takeda Pharmaceutical, Bayer Yakuhin, Bristol-Myers Squibb, Taiho Pharmaceutical, MSD, Ono Pharmaceutical, Merck Biopharma and Miyarisan Pharmaceutical, outside the submitted work; Dr. Ken Shimada reports honoraria from Taiho, Chugai, Yakult, Bristol-Myers Squibb, Takeda, Merck Biopharma and Eli Lilly, and grants and personal fees from Taiho, Chugai, and Ono, outside the submitted work; Prof. Yasuhide Yamada reports research grants from Chugai and honoraria from Janssen, Behringer-Ingelheim, Taiho, Ono outside the submitted work; Prof. Chikashi Ishioka reports research funds from Hitachi and Riken Genesis and research grants from Chugai, Taiho, Asahi Kasei, Daiichi-Sankyo, Takeda, and Ono and honoraria from Chugai and Daiichi-Sankyo, outside the submitted work.
